NOVOS

NOVOS

NOVOS is a biopharma, biotechnology, and health care startup founded in 2018, headquartered in the United States. The company is dedicated to making the latest scientific advances in longevity accessible and achievable for all, with the slogan #YoungerForLonger. NOVOS leverages science and data to develop nutraceuticals aiming to extend human lifespan.

The company prides itself on creating supplements that are based on the best available science, crafted in collaboration with top experts in the field of aging. These supplements utilize scientifically validated ingredients that have shown to extend lifespan in various organisms. They are also focused on the 12 mechanisms of aging to leverage synergistic effects and include ingredients with proven beneficial effects on human aging.

One of NOVOS' unique selling points is its scientific advisory team, comprising biochemists, geneticists, and professors from esteemed institutions such as Harvard, MIT, University of Liverpool, University of Washington, and the Salk Institute. These experts have received prestigious accolades and have been prominently featured in renowned publications and media outlets, cementing their status as pioneers in the longevity field.

As a Public Benefit Corporation (PBC), NOVOS allocates a portion of its profits and equity to support nonprofits in the longevity science space, such as the 501(c)(3) organization, Life Extension Advocacy Foundation (LEAF). Furthermore, the company provides free educational content aimed at promoting longer, healthier lives, underscoring its commitment to advancing longevity science.

The latest investment in NOVOS came from Audrey Capital in an Angel Round investment on 01 January 2022. This investment underscores the growing interest and potential of NOVOS in the biopharma and biotechnology sectors.